Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Norma O'Donovan"'
Autor:
Martina S. J. McDermott, Brigid C. Browne, Neil T. Conlon, Neil A. O’Brien, Dennis J. Slamon, Michael Henry, Paula Meleady, Martin Clynes, Paul Dowling, John Crown, Norma O’Donovan
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/e0d45aa2e7a441378b538287bcf79ac3
Autor:
Sandra Roche, Patricia Gaule, Deirdre Winrow, Nupur Mukherjee, Fiona O'Neill, Neil T Conlon, Justine Meiller, Denis M Collins, Alexandra Canonici, Mohammed Ibrahim Fawsi, Alejandra Estepa-Fernández, Stephen F Madden, John Crown, Norma O'Donovan, Alex J Eustace
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282512 (2023)
Triple Negative Breast Cancer (TNBC), a subtype of breast cancer, has fewer successful therapeutic therapies than other types of breast cancer. Insulin-like growth factor receptor 1 (IGF1R) and the Insulin receptor (IR) are associated with poor outco
Externí odkaz:
https://doaj.org/article/b9644b158fb94f80a2b68dadca1eef19
Autor:
Sinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, Yasir Elamin, Shereen Rafee, Mattia Cremona, Clare Morgan, Stephen Madden, Khairun I. Abdul-Jalil, Kathy Gately, Angela Farrelly, Elaine W. Kay, Susan Kennedy, Kenneth O’Byrne, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Alexander J. Eustace, Joanna Fay, Robert Cummins, Anthony O’Grady, Roshni Kalachand, Norma O’Donovan, Fergal Kelleher, Aine O’Reilly, Mark Doherty, John Crown, Bryan T. Hennessy
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-14 (2020)
Abstract Background An increasing number of anti-cancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Successful use of these therapies is dependent on the presence or absence of somatic mutation
Externí odkaz:
https://doaj.org/article/b0a3ce4f632e46aeb43bc18b4d3e61a7
Autor:
Nupur Mukherjee, Alacoque Browne, Laura Ivers, Tapesh Santra, Mattia Cremona, Bryan T. Hennessy, Norma O’Donovan, John Crown, Walter Kolch, Dirk Fey, Alex J. Eustace
Publikováno v:
Journal of Personalized Medicine, Vol 12, Iss 8, p 1277 (2022)
Triple negative breast cancer (TNBC) remains a therapeutic challenge due to the lack of targetable genetic alterations and the frequent development of resistance to the standard cisplatin-based chemotherapies. Here, we have taken a systems biology ap
Externí odkaz:
https://doaj.org/article/3d2a12f29f2f44e78dc4c41944a3e9ee
Autor:
Astrid O. Leech, Sri HariKrishna Vellanki, Emily J. Rutherford, Aoife Keogh, Hanne Jahns, Lance Hudson, Norma O’Donovan, Siham Sabri, Bassam Abdulkarim, Katherine M. Sheehan, Elaine W. Kay, Leonie S. Young, Arnold D. K. Hill, Yvonne E. Smith, Ann M. Hopkins
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-18 (2018)
Abstract Background Junctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer phenotypes, including human epidermal growth factor receptor-2 (HER2)-positive d
Externí odkaz:
https://doaj.org/article/72a1a9c60a1942e4bc9a56db7d21098a
Autor:
Alex J Eustace, Neil T Conlon, Martina S J McDermott, Brigid C Browne, Patrick O’Leary, Frankie A Holmes, Virginia Espina, Lance A Liotta, Joyce O’Shaughnessy, Clair Gallagher, Lorraine O’Driscoll, Sweta Rani, Stephen F Madden, Neil A O’Brien, Charles Ginther, Dennis Slamon, Naomi Walsh, William M Gallagher, Radoslaw Zagozdzon, William R Watson, Norma O’Donovan, John Crown
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-14 (2018)
Abstract Background Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of
Externí odkaz:
https://doaj.org/article/5de7181f330d45b98eeaa2bf7e64c819
Autor:
Alexandra Canonici, Alacoque L. Browne, Mohamed F. K. Ibrahim, Kevin P. Fanning, Sandra Roche, Neil T. Conlon, Fiona O’Neill, Justine Meiller, Mattia Cremona, Clare Morgan, Bryan T. Hennessy, Alex J. Eustace, Flavio Solca, Norma O’Donovan, John Crown
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited therapeutic options. Epidermal growth factor receptor (EGFR) has been shown to be over-expressed in TNBC and represents a rational treatment targe
Externí odkaz:
https://doaj.org/article/30ed8d6b4bc948429c56a9912d216c9d
Autor:
Sinead Toomey, Alexander J. Eustace, Joanna Fay, Katherine M. Sheehan, Aoife Carr, Malgorzata Milewska, Stephen F. Madden, Ausra Teiserskiene, Elaine W. Kay, Norma O’Donovan, William Gallagher, Liam Grogan, Oscar Breathnach, Janice Walshe, Catherine Kelly, Brian Moulton, M. John Kennedy, Guiseppe Gullo, Arnold D. Hill, Colm Power, Deirdre Duke, Niamh Hambly, John Crown, Bryan T. Hennessy
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-12 (2017)
Abstract Background The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family muta
Externí odkaz:
https://doaj.org/article/2df2fd828ec74507b4f5c59ad4f1e106
Autor:
Giuseppe Gullo, Alex J. Eustace, Alexandra Canonici, Denis M. Collins, Michael J. Kennedy, Liam Grogan, Oscar Breathhnach, John McCaffrey, Maccon Keane, Michael J. Martin, Rajnish Gupta, Gregory Leonard, Miriam O’Connor, Paula M. Calvert, Paul Donnellan, Janice Walshe, Enda McDermott, Kathleen Scott, Andres Hernando, Imelda Parker, David W. Murray, Alice C. O’Farrell, Ashwini Maratha, Patrick Dicker, Mairin Rafferty, Verena Murphy, Norma O’Donovan, William M. Gallagher, Bonnie Ky, Dimitrios Tryfonopoulos, Brian Moulton, Annette T. Byrne, John Crown
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: Combining bevacizumab and chemotherapy produced superior response rates compared with chemotherapy alone in metastatic breast cancer. As bevacizumab may cause hypertension (HTN) and increase the risk of cardiac failure, we performed a pil
Externí odkaz:
https://doaj.org/article/dd373e9d21d44deea251f3cc0cedb80b
Autor:
Tapesh Santra, Sandra Roche, Neil Conlon, Norma O'Donovan, John Crown, Robert O'Connor, Walter Kolch
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0177058 (2017)
Molecularly targeted therapeutics hold promise of revolutionizing treatments of advanced malignancies. However, a large number of patients do not respond to these treatments. Here, we take a systems biology approach to understand the molecular mechan
Externí odkaz:
https://doaj.org/article/e1dff045538248eb9ca20ebb0272e39e